宜宾哪个医院做双眼皮好的(宜宾做完双眼皮多久能洗脸) (今日更新中)

The Trump administration issued an order on Friday that will attempt to ban Americans from downloading Chinese-owned social media apps TikTok and WeChat beginning Sunday.The order issued by Commerce Department Sec. Wilbur Ross, requires companies like Apple and Google to remove the apps from their online stores by Sunday. It also orders that all U.S. companies cease working with WeChat to transfer funds or process payments in the app.It's currently unclear if Apple and Google will choose to comply with the Commerce Department's order or if they will choose to file a lawsuit to keep the apps in their stores.“Today’s actions prove once again that President Trump will do everything in his power to guarantee our national security and protect Americans from the threats of the Chinese Communist Party," Ross said in a statement. “At the President’s direction, we have taken significant action to combat China’s malicious collection of American citizens’ personal data, while promoting our national values, democratic rules-based norms, and aggressive enforcement of U.S. laws and regulations.”There will be no penalty for those who have already downloaded the app and continue to use it to communicate. However, the order says that messaging on the apps "could be directly or indirectly impaired” by the order.In the case of TikTok, the order stipulates that its parent company, ByteDance, has until Nov. 12 to "resolve" its national security concerns. ByteDance has been in talks to sell its American business with U.S. software company Oracle.Privacy experts have raised concerns about both Chinese-owned apps, saying Americans' personal information could fall into the hands of the Chinese government. In August, Trump signed an order that set a Sept. 20 deadline for the sale of TikTok's U.S. business."Each collects vast swaths of data from users, including network activity, location data, and browsing and search histories," the Commerce Department's order reads. "Each is an active participant in China’s civil-military fusion and is subject to mandatory cooperation with the intelligence services of the CCP. This combination results in the use of WeChat and TikTok creating unacceptable risks to our national security." 2242

The Supreme Court is allowing Florida to enforce a law that bars ex-felons from voting who still owe court fees or fines.Thursday’s decision by the Supreme Court denied the request in front of them to lift the order of lower court rulings. Their decision allows the Florida law to move forward without declaring the law to be unconstitutional or limit ongoing court challenges.Liberal Justices Sonia Sotomayor, Ruth Bader Ginsburg and Elena Kagan dissented."This Court's order prevents thousands of otherwise eligible voters from participating in Florida's primary election simply because they are poor," Sotomayor wrote in the dissent."This Court's inaction continues a trend of condoning (disenfranchisement)," she added.The law is expected to impact roughly 1.4 million people in Florida. Amendment 4, passed by Florida voters in 2018, allowed most ex-felons to register to vote, with exceptions for those convicted of certain crimes. In 2019, Governor Ron DeSantis signed into law additions to Amendment 4 that required fines, fees and restitution be paid first before ex-felons could register to vote. Thursday's decision from the Supreme Court comes just days before the voter registration deadline in Florida. The state's primary election is scheduled for August 18 and voters must register by July 20. 1320

The state of Oregon became the first in the nation to decriminalize small amounts of hard drugs like heroin and cocaine by overwhelmingly passing Measure 110 on Tuesday.According to The Oregonian, the measure will reduce misdemeanor drug possession to a non-criminal violation, punishable by measures similar to a traffic stop. Violators will be given a ticket and a 0 fine, or be given the option of being screened for a subtance abuse disorder.Those found with larger amounts of drugs, who would have previously been charged with a felony, will now face a misdemeanor charge. The measure also redirects tax revenue from the sale of legal marijuana in the state toward Addiction Recover Centers, where people are screened for drug use and can also receive treatment for drug addiction.Supporters of the measure say the new policy will reduce the state's jail population, and in particular, free many offenders of non-violent crimes. Supporters also say the bill will promote racial equality in the state, as drug laws disproportionately affect Black people and other people of color.Opponents of the measure say it promotes drug use and will lead to more overdose deaths and overwhelm addiction centers in the state.The Oregonian also reports that the measure received funding from many out-of-state donors, including Facebook founder and CEO Mark Zuckerberg.The Associated Press reports that the measure passed with about 60% support.In addition to decriminalizing hard drug use, Oregon also legalized the sale and recreational use of Psilocybin, or magic mushrooms. The Associated Press reports that the measure passed with 56% support. 1650

The White House says President Donald Trump was never briefed on intelligence that Russia had put a bounty on U.S. soldiers in Afghanistan because there wasn’t corroborating evidence. But former intelligence officials say presidents are routinely informed about intelligence even when it’s not definitively confirmed. Former intelligence officials says it strains credulity to think that Trump wouldn’t have been told of something so important, whether corroborated or not. Intelligence that may be on shaky ground today may foreshadow tomorrow’s calamity, so briefers are expected to ensure presidents have the fullest possible picture to prepare for something that may soon require full attention. 707

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

来源：资阳报